Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin embedded material

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  De Leng, Wendy W J ^a   Gadellaa Van Hooijdonk, Christa G ^a,b   Barendregt Smouter, Françoise A S ^a,b   Koudijs, Marco J ^a,b   Nijman, Ies ^a,b   Hinrichs, John W J ^a   Cuppen, Edwin ^a,b   Van Lieshout, Stef ^a,b   Loberg, Robert D ^d   De Jonge, Maja ^b,e   Voest, Emile E ^c   De Weger, Roel A ^a   Steeghs, Neeltje ^b,c   Langenberg, Marlies H G ^a,b   Sleijfer, Stefan ^b,e   Willems, Stefan M ^a,b   Lolkema, Martijn P ^a,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Netherlands Center for Personalized Cancer Treatment   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d AMGEN INC   (United States)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; FRESH FROZEN TISSUE; GENETIC VARIABILITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; RELIABILITY; SENSITIVITY ANALYSIS; SOMATIC MUTATION; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TISSUE FIXATION;

DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 84960447255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149405     Document Type: Article

References (40)

1. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008; 452(7189):872-6. Epub 2008/04/19. doi: nature06884 [pii] doi: 10.1038/nature06884 PMID: 18421352.
2. Martinez DA, Nelson MA. The next generation becomes the now generation. PLoS Genet. 2010; 6(4): e1000906. Epub 2010/04/14. doi: 10.1371/journal.pgen.1000906 PMID: 20386747; PubMed Central PMCID: PMC2851573.
3. Hinrichs JW, van Blokland WT, Moons MJ, Radersma RD, Radersma-van Loon JH, de Voijs CM, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015; 143(4):573-8. Epub 2015/03/18. doi: 143/4/573 [pii] doi: 10.1309/AJCP40XETVYAMJPY PMID: 25780010.
4. Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. Epub 2012/06/23. doi: nature11219 [pii] doi: 10.1038/nature11219 PMID: 22722843; PubMed Central PMCID: PMC3436069.
5. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol. 2012; 30(5):434-9. Epub 2012/04/24. doi: nbt.2198 [pii] doi: 10.1038/nbt.2198 PMID: 22522955.
6. Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol. 2014; 4:78. Epub 2014/05/27. doi: 10.3389/fonc.2014.00078 PMID: 24860780; PubMed Central PMCID: PMC4029014.
7. Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn. 2014; 16(1):89-105. Epub 2013/11/12. doi: S1525-1578(13)00219-5 [pii] doi: 10.1016/j.jmoldx.2013.10.002 PMID: 24211365.
8. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. Epub 2013/10/22. doi: nbt.2696 [pii] doi: 10.1038/nbt.2696 PMID: 24142049.
9. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC genomics. 2012; 13:341. Epub 2012/07/26. doi: 10.1186/1471-2164-13-341 PMID: 22827831; PubMed Central PMCID: PMC3431227.
10. Gleeson FC, Kipp BR, Kerr SE, Voss JS, Graham RP, Campion MB, et al. Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2015; 13(1):202-6. Epub 2014/07/06. doi: 10.1016/j.cgh.2014.06.024 PMID: 24997326.
11. Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014; 14:13. Epub 2014/01/15. doi: 1471-2407-14-13 [pii] doi: 10.1186/1471-2407-14-13 PMID: 24410877; PubMed Central PMCID: PMC3893431.
12. Sie D, Snijders PJ, Meijer GA, Doeleman MW, van Moorsel MI, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr). 2014; 37(5):353-61. Epub 2014/09/12. doi: 10.1007/s13402-014-0196-2 PMID: 25209392.
13. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015; 121(4):631-9. Epub 2014/10/28. doi: 10.1002/cncr.29089 PMID: 25345567.
14. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The oncologist. 2014; 19(6):616-22. Epub 2014/05/07. doi: 10.1634/theoncologist.2014-0011 PMID: 24797823; PubMed Central PMCID: PMC4041676.
15. Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, et al. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clinical biochemistry. 2015; 48(13-14):908-10. Epub 2015/04/15. doi: 10.1016/j.clinbiochem.2015.04.003 PMID: 25872148.
16. Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, et al. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol. 2015; 68(1):64-8. Epub 2014/11/08. doi: 10.1136/jclinpath-2014-202691 PMID: 25378536.
17. Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol. 2014; 141 (6):856-66. Epub 2014/05/20. doi: AJCPMWGWGO34EGOD [pii] doi: 10.1309/AJCPMWGWGO34EGOD PMID: 24838331; PubMed Central PMCID: PMC4332779.
18. Mafficini A, Amato E, Fassan M, Simbolo M, Antonello D, Vicentini C, et al. Reporting tumor molecular heterogeneity in histopathological diagnosis. PLoS One. 2014; 9(8):e104979. Epub 2014/08/16. doi: 10.1371/journal.pone.0104979 PONE-D-14-16410 [pii]. PMID: 25127237; PubMed Central PMCID: PMC4134249.
19. McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013; 8(7):e69604. Epub 2013/08/08. doi: 10.1371/journal. pone.0069604 PONE-D-13-05730 [pii]. PMID: 23922754; PubMed Central PMCID: PMC3724913.
20. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, et al. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014; 141(4):559-72. Epub 2014/03/13. doi: 141/4/559 [pii] doi: 10.1309/AJCP1JUGQMW7ZNTL PMID: 24619758.
21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. Epub 2009/05/20. doi: 10.1093/bioinformatics/btp324 PMID: 19451168; PubMed Central PMCID: PMC2705234.
22. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010; 26(5):589-95. Epub 2010/01/19. doi: 10.1093/bioinformatics/btp698 PMID: 20080505; PubMed Central PMCID: PMC2828108.
23. Ning Z, Cox AJ, Mullikin JC. SSAHA: a fast search method for large DNA databases. Genome research. 2001; 11(10):1725-9. Epub 2001/10/10. doi: 10.1101/gr.194201 PMID: 11591649; PubMed Central PMCID: PMC311141.
24. Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012; 28(14):1838-44. Epub 2012/05/10. doi: 10.1093/bioinformatics/bts280 PMID: 22569178; PubMed Central PMCID: PMC3389770.
25. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26(16):2069-70. Epub 2010/06/22. doi: btq330 [pii] doi: 10.1093/bioinformatics/btq330 PMID: 20562413; PubMed Central PMCID: PMC2916720.
26. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24-6. Epub 2011/01/12. doi: nbt.1754 [pii] doi: 10.1038/nbt. 1754 PMID: 21221095; PubMed Central PMCID: PMC3346182.
27. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002; 161(6):1961-71. Epub 2002/12/06. doi: S0002-9440(10)64472-0 [pii] doi: 10.1016/S0002-9440(10)64472-0 PMID: 12466110; PubMed Central PMCID: PMC1850907.
28. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol. 1999; 155(5):1467-71. Epub 1999/11/07. doi: S0002-9440(10)65461-2 [pii] doi: 10.1016/S0002-9440(10)65461-2 PMID: 10550302; PubMed Central PMCID: PMC1866966.
29. Smits AJ, Kummer JA, de Bruin PC, Bol M, van den Tweel JG, Seldenrijk KA, et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol. 2014; 27 (2):168-74. Epub 2013/07/28. doi: modpathol2013134 [pii] doi: 10.1038/modpathol.2013.134 PMID: 23887293.
30. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006; 66 (16):7854-8. Epub 2006/08/17. doi: 66/16/7854 [pii] doi: 10.1158/0008-5472.CAN-06-1951 PMID: 16912157.
31. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. Epub 2008/07/04. doi: NEJMoa0800668 [pii] doi: 10.1056/NEJMoa0800668 PMID: 18596266; PubMed Central PMCID: PMC3551471.
32. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008; 99(5):929-35. Epub 2008/03/08. doi: CAS782 [pii] doi: 10.1111/j.1349-7006.2008.00782.x PMID: 18325048.
33. Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014; 25(10):1959-65. Epub 2014/09/04. doi: mdu288 [pii] doi: 10.1093/annonc/mdu288 PMID: 25185240.
34. Blow N. Tissue preparation: Tissue issues. Nature. 2007; 448(7156):959-63. Epub 2007/08/24. doi: 448959a [pii] doi: 10.1038/448959a PMID: 17713539.
35. Dietrich D, Uhl B, Sailer V, Holmes EE, Jung M, Meller S, et al. Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition. PLoS One. 2013; 8(10):e77771. Epub 2013/10/25. doi: 10.1371/journal.pone.0077771 PONE-D-13-18657 [pii]. PMID: 24155973; PubMed Central PMCID: PMC3796491.
36. Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One. 2014; 9(5):e98187. Epub 2014/06/01. doi: 10. 1371/journal.pone.0098187 PONE-D-14-11652 [pii]. PMID: 24878701; PubMed Central PMCID: PMC4039489.
37. Latham GJ. Next-generation sequencing of formalin-fixed, paraffin-embedded tumor biopsies: navigating the perils of old and new technology to advance cancer diagnosis. Expert Rev Mol Diagn. 2013; 13 (8):769-72. Epub 2013/10/15. doi: 10.1586/14737159.2013.845090 PMID: 24117229.
38. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 2013; 340(2):284-95. Epub 2012/11/24. doi: S0304-3835(12)00672-6 [pii] doi: 10.1016/j. canlet.2012.11.025 PMID: 23174106.
39. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn. 2013; 15(5):623-33. Epub 2013/07/03. doi: S1525-1578(13)00091-3 [pii] doi: 10.1016/j.jmoldx.2013. 05.004 PMID: 23810758.
40. Hoogstraat M, Hinrichs JW, Besselink NJ, Radersma-van Loon JH, de Voijs CM, Peeters T, et al. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. J Mol Diagn. 2015; 17(1):10-8. Epub 2014/12/03. doi: S1525-1578(14)00177-9 [pii] doi: 10.1016/j. jmoldx.2014.09.004 PMID: 25445215.